Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Aducanumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biogen in up to $1.8 bln deal as rare diseases take center stage
    Biogen in up to $1.8 bln deal as rare diseases take center stage

    23 May 2024

    // REUTERS

    https://www.reuters.com/markets/deals/biogen-buy-human-immunology-biosciences-up-18-bln-deal-2024-05-22/

    REUTERS
    23 May 2024
    Share Share
    FDA revises guidance on predicting Alzheimer's drug benefits
    FDA revises guidance on predicting Alzheimer's drug benefits

    12 Mar 2024

    // Gabrielle Masson FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/new-fda-guidelines-consider-amyloid-reduction-reasonably-likely-predict-clinical-benefit

    Gabrielle Masson FIERCE BIOTECH
    12 Mar 2024
    Share Share
    Biogen drops Alzheimer's drug Aduhelm, ending a 17-year chapter
    Biogen drops Alzheimer's drug Aduhelm, ending a 17-year chapter

    01 Feb 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-discontinue-development-older-alzheimers-drug-aduhelm-2024-01-31/

    REUTERS
    01 Feb 2024
    Share Share
    Biogen comes out ahead in Aduhelm-related investor lawsuit
    Biogen comes out ahead in Aduhelm-related investor lawsuit

    31 Mar 2023

    // Zoey Becker FIERCE PHARMA

    https://www.fiercepharma.com/pharma/biogen-scores-win-massachusetts-judge-dismisses-investor-lawsuit

    Zoey Becker FIERCE PHARMA
    31 Mar 2023
    Share Share
    VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
    VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm

    14 Mar 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/va-to-cover-eisais-new-alzheimers-drug-after-declining-to-cover-aduhelm/

    Zachary Brennan ENDPTS
    14 Mar 2023
    Share Share
    Dunn with the FDA: head of agency's neuroscience unit to depart
    Dunn with the FDA: head of agency's neuroscience unit to depart

    27 Feb 2023

    // Max Bayer FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/dunn-fda-head-neuroscience-unit-depart

    Max Bayer FIERCE BIOTECH
    27 Feb 2023
    Share Share